Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Statins protect against hepatocellular carcinoma

10 Mar 2018
Statin, a blood cholesterol-lowering medicine, reduces sharply in blood cholesterol levels among ACS patients.

High-risk patients may benefit from a protective effect of statins against hepatocellular carcinoma (HCC), a recent study suggests. This effect appears to be greater in patients with diabetes mellitus (DM) or liver cirrhosis (LC).

Researchers drew data from the 2002–2013 National Health Insurance Service Physical Health Examination Cohort in the Republic of Korea. Multivariable conditional logistic regression analysis was performed to determine the association of HCC with statin use.

The use of statins was significantly less common in 1,642 HCC patients than in 8,210 age-, sex- and index date-matched controls, including simvastatin (odds ratio [OR], 0.44; 95 percent CI, 0.33–0.58), atorvastatin (OR, 0.49; 0.37–0.65), lovastatin (OR, 0.34; 0.16–0.73), rosuvastatin (OR, 0.56; 0.31–0.98) and pitavastatin (OR, 0.31; 0.13–0.77).

There was a significant association between statin use and a lower risk of HCC incidence relative to nonuse (adjusted OR, 0.44; 0.33–0.58).

Cumulative doses of statin also appeared to yield a trend of risk reduction. The corresponding adjusted ORs for <180, 180–365, 365–720 and 720 cumulative defined daily doses of statin use were 0.45 (0.32–0.64), 0.56 (0.31–1.00), 0.41 (0.22–0.76) and 0.30 (0.14–0.63).

The inhibitory effect of statins on HCC was stronger in patients with DM (adjusted OR, 0.28; 0.17–0.46) and LC (adjusted OR, 0.39; 0.26–0.70) relative to statin users without the said conditions (adjusted OR for DM, 0.53; 0.39–0.73; adjusted OR for LC, 0.42; 0.32–0.57).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.